Should we still prescribe digoxin in mild-to-moderate heart failure? Is quality of life the issue rather than

J Soler-Soler1, G Permanyer-Miralda

  • 1Servicio de Cardiología, Hospital General Universitari Vall d'Hebron, Barcelona, Spain.

European Heart Journal
|January 14, 1999
PubMed

Insights

Digoxin does not improve survival in heart failure but may help with symptoms. This study suggests digoxin offers symptomatic improvement for mild to moderate heart failure patients, though effects are modest.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • The Digitalis Investigation Group (DIG) study found digoxin does not improve heart failure survival.
  • However, its role in symptomatic improvement for mild to moderate heart failure remains a key clinical question.

Purpose of the Study:

  • To evaluate the efficacy of digoxin for symptomatic improvement in patients with mild to moderate heart failure.
  • To address the lack of precise clinical measures for categorizing heart failure severity.

Main Methods:

  • Analysis of data from multiple clinical trials, including the DIG study and others like the Randomized Assessment of the effect of Digoxin on Inhibitors of ACE Study.
  • Utilizing subgroup analyses and direct clinical measures of patient outcomes.

Main Results:

  • Digoxin demonstrated a beneficial clinical effect, particularly in subgroups with less severe heart failure.
  • Other trials using direct clinical measures indicated definite symptomatic improvement in patients on digoxin therapy for mild heart failure.
  • The magnitude of symptomatic benefit from digoxin therapy was generally modest.

Conclusions:

  • Digoxin can be considered effective for symptomatic improvement in patients with mild to moderate heart failure.
  • Despite modest effects and some safety concerns, its use for symptom management is supported.
  • Physician discretion is advised for initiating digoxin therapy due to the small effect size.

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.6K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
632
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753